Modulation of c-kit expression in pancreatic adenocarcinoma: A novel stem cell marker responsible for the progression of the disease

Acta Histochemica

Volumn 116, Issue 1, 2014, Pages 197-203

  Amsterdam, Abraham ^a   Raanan, Calanit ^a   Polin, Nava ^a   Melzer, Ehud ^b   Givol, David ^a   Schreiber, Letizia ^c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

cells; Diabetes; Insulin; KRAS; LGR5; Nanog

Indexed keywords

STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

AGED; CANCER STEM CELL; DISEASE COURSE; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

AGED; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 84894905415     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.07.002     Document Type: Article

References (35)

1. Amsterdam A., Raanan C., Schreiber L., Freyhan O., Fabrikant Y., Melzer E., et al. Differential localization of LGR5 and Nanog in clusters of colon cancer stem cells. Acta Histochem 2013, 115:320-329.
2. Amsterdam A., Raanan C., Schreiber L., Polin N., Givol D. LGR5 and Nanog identify stem cell signature of pancreas beta cells which initiate pancreatic cancer. Biochem Biophys Res Commun 2013, 433:157-162.
3. Antonescu C.R. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol 2008, 21:S31-S36.
4. Ashman L.K., Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Invest Drugs 2013, 22:103-115.
5. Avramis I.A., Laug W.E., Sausville E.A., Avramis V.I. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol 2003, 52:307-318.
6. Balic A., Dorado J., Alonso-Gomez M., Heeshen C. Stem cells as the root of the pancreatic ductal adenocarcinoma. Exp Cell Res 2012, 318:691-704.
7. Bateman A.C., Judd M., Radenkovic D., Johnson C.D. CD117/KIT expression in pancreatic adenocarcinoma. Pancreas 2008, 36:76-79.
8. Burgos-Ojeda D., BRueda B.R., Buckanovich R.J. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 2012, 322:1-7.
9. Curley M.D., Garrett L.A., Schorge J.O., Foster R., Rueda B.R. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011, 16:368-392.
10. Feng Z.C., Li J., Turco B.A., Riopel M., Yee S.P., Wang R. Critical role of c-Kit in beta cell function: increased insulin secretion and protection against diabetes in a mouse model. Diabetologia 2012, 55:2214-2225.
11. Giantin M., Vascellari M., Morello E.M., Capello K., Vercelli A., Granato A., et al. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. J Vet Diagn Invest 2012, 24:116-126.
12. Heinrich M.C., Marino-Enriquez A., Presnell A., Donsky R.S., Griffith D.J., McKinley A., et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther 2012, 11:1770-1780.
13. Hennig R., Ding X.Z., Adrian T.E. On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 2004, 19:999-1011.
14. Herzel A.F., Kimmelman A.C., Stanger B.Z., Berdeesy N., Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20:1218-1249.
15. Kaligin M.S., Gumerova A.A., Titova M.A., Andreeva D.I., Sharipova ÉI, Kiiasov A.P. C-kit is a marker of human pancreatic endocrinocyte stem cells. Morfologiia 2011, 140:32-37.
16. Kashiwagi S., Yashiro M., Takashima T., Aomatsu N., Kawajiri H., Ogawa Y., et al. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. Br J Surg 2013, 100:490-496.
17. Kim J.Y., Yoo Y.S., Kwon J.E., Kim H.J., Park K. Fine-needle aspiration cytology with c-kit immunocytochemical staining in the diagnosis of Warthin's tumor. Acta Cytol 2012, 56:474-480.
18. Kong B., Michalski C.W., Erkan M., Friess H., Kleeff J. From tissue turnover to the cell of origin for pancreatic cancer. Nat Rev Gastroenterol Hepatol 2011, 8:467-472.
19. Kong B., Michalski C.W., Kleeff J. Tumor initiating cells in pancreatic cancer: a critical view. World J Stem cells 2009, 1:8-10.
20. Krishnamurthy M., Ayazi F., Li J., Lyttle A.W., Woods M., Wu Y., et al. c-Kit in early onset of diabetes: a morphological and functional analysis of pancreatic beta-cells in c-KitW-v mutant mice. Endocrinology 2007, 148:5520-5530.
21. Kumar-Shina C., Wei I., Simeone D.W. Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu. Curr Opin Gastroenterol 2012, 28:516-522.
22. Lengyel E., Sawada K., Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 2007, 7:77-84.
23. Lennartsson J., Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012, 92:1619-1649.
24. Li J., Goodyer C.G., Fellows F., Wang R. Stem cell factor/c-Kit interactions regulate human islet-epithelial cluster proliferation differentiation. Int J Biochem Cell Biol 2006, 38:961-972.
25. Li J., Quirt J., Do H.Q., Lyte K., Fellows F., Goodyer C.G., et al. Expression of c-Kit receptor tyrosine kinase and effect on beta-cell development in the human fetal pancreas. Am J Physiol Endocrinol Metab 2007, 293:E475-E483.
26. Löbke C., Laible M., Rappl C., Ruschhaupt M., Sahin O., Arlt D., et al. Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling. Proteomics 2008, 8:1586-1594.
27. Mangana J., Levesque M.P., Karpova M.B., Dummer R. Sorafenib in melanoma. Expert Opin Invest Drugs 2012, 21:557-568.
28. Merkwitz C., Lochhead P., Tsikolia N., Koch D., Sygnecka K., Sakurai M., et al. Expression of KIT in the ovary, and the role of somatic precursor cells. Prog Histochem Cytochem 2011, 46:131-184.
29. Miettinen M., Lasota J. Gastrointestinal stromaltumors. Arch Pathol Lab Med 2006, 130:1466-1478.
30. Pandol S.J., Apte M.V., Wilson J.S. The burning question: why is smoking a risk factor for pancreatic cancer?. Pancreatology 2012, 12:344-349.
31. Sammarco I., Capurso G., Coppola L., Bonifazi A.P., Cassetta S., Delle Fave G., et al. Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients. Int J Colorectal Dis 2004, 19:545-553.
32. Schallier D., Trullemans F., Fontaine C., Decoster L., De Greve J. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res 2009, 29:5225-5228.
33. Soria J.C., Blay J.Y., Spano J.P., Pivot X., Coscas Y., Khayat D. Added value of molecular targeted agents in oncology. Ann Oncol 2011, 22:1703-1716.
34. Tsuura Y., Hiraki H., Watanabe K., Igarashi S., Shimamura K., Fukuda T., et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994, 424:135-141.
35. Wu Y., Li J., Saleem S., Yee S.P., Hardikar A.A., Wang R. c-Kit and stem cell factor regulate PANC-1 cell differentiation into insulin- and glucagon-producing cells. Lab Invest 2010, 90:1373-1384.